RT Conference Proceedings
T1 Activity of OSE-2101 in HLA-A2+non-small cell lung cancer (NSCLC) patients after failure to immune checkpoint inhibitors (ICI): Step 1 results of phase III ATALANTE-1 randomised trial
A1 Giaccone, G.
A1 Felip, E.
A1 Cobo, M.
A1 Garcia Campelo, R.
A1 Denis, F.
A1 Quoix, E.
A1 Madroszyk, A.
A1 Debieuvre, D.
A1 Hilgers, W.
A1 Moran, T.
A1 Galetta, D.
A1 Romano, G. D.
A1 Cappuzzo, F.
A1 Robinet, G.
A1 Masson, P.
A1 Viteri, S.
A1 Peled, N.
A1 Costantini, D.
A1 Dziadziuszko, R.
A1 Besse, B.
PB Elsevier
SN 0923-7534
YR 2020
FD 2020-09-01
LK https://hdl.handle.net/10668/26992
UL https://hdl.handle.net/10668/26992
LA en
DS RISalud
RD Apr 7, 2025